摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-吗啉基-3-硝基苯 | 116922-22-6

中文名称
4-吗啉基-3-硝基苯
中文别名
4-(3-硝基苯基)吗啉;吗啉,4-(3-硝基苯基)
英文名称
3-morpholinonitrobenzene
英文别名
4-(3-nitrophenyl)morpholine;N-(3-nitrophenyl)morpholine;3-nitro-1-morpholin-4-yl-benzene
4-吗啉基-3-硝基苯化学式
CAS
116922-22-6
化学式
C10H12N2O3
mdl
——
分子量
208.217
InChiKey
DKECFAGKGYRYAT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    108-110 °C
  • 沸点:
    365.5±37.0 °C(Predicted)
  • 密度:
    1.265±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    15
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    58.3
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 危险类别码:
    R36/37/38
  • 海关编码:
    2934999090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    存于室温、密封且干燥的环境中。

SDS

SDS:8af6cb28ce0a3a3269f68deeb03f05ca
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS<br/>[FR] DIARYLURÉES EN TANT QUE MODULATEURS ALLOSTÉRIQUES DE CB1
    申请人:RTI INT
    公开号:WO2018209030A1
    公开(公告)日:2018-11-15
    The present invention provides novel diarylurea derivatives (compounds of formula (I)) and their uses. The compounds of the present invention are demonstrated to be allosteric modulators of the CB1 receptor, and therefore useful for the treatment of diseases and conditions mediated by CB1.
    本发明提供了新颖的二芳基生物(式(I)化合物)及其用途。本发明的化合物被证明是CB1受体的变构调节剂,因此对于治疗由CB1介导的疾病和症状是有用的。
  • Compounds
    申请人:Hummersone Geoffrey Marc
    公开号:US20060199804A1
    公开(公告)日:2006-09-07
    Compounds of formula I: A-B-C  (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof wherein: B is selected from the group consisting of: where R N is H or Me; or B is a divalent C 5 heterocyclic residue containing one or two ring heteroatoms; A is: R A3 and R A5 are independently selected from halo, OR O and R AC , where R O is H or Me, and R AC is H or C 1-4 alkyl; X A is selected from N and CR A4 , where R A4 is selected from H, OR O , CH 2 OH, CO 2 H, NHSO 2 Me and NHCOMe; R A2 and R A6 are independently selected from H, halo and OR O ; or R A3 and R A4 together with the carbon atoms to which they are attached, or RA2 and R A3 together with the carbon atoms to which they are attached, may form a C 5-6 heterocylic or heteroaromatic ring, containing at least one nitrogen ring atom; where if X is not N, 1, 2, or 3 of R A2 to R A6 are not H; C is: where X is selected from N and CH, Y is selected from N and CH, and Z is selected from N and CR C6 ; R C3 is selected from H, halo and an optionally substituted N-containing C 5-7 heterocyclic group; R C5 is a group selected from: which group may be selected by one or two C 1-4 alkyl groups or a carboxy group; R C6 is H; or, when X and Y are N, R C5 and R C6 (when Z is CR C6 ) together with the carbon atoms to which they are attached may form a fused C 6 aromatic ring selected from the group consisting of:
    化合物的化学式I: A-B-C  (I) 及其异构体、盐、溶剂合物、化学保护形式和前药,其中: B选自以下组合: 其中R N 为H或Me; 或B是含有一个或两个环异原子的二价C 5 杂环残基; A为: R A3 和R A5 独立选择自卤、OR O 和R AC ,其中R O 为H或Me,R AC 为H或C 1-4 烷基; X A 选自N和CR A4 ,其中R A4 选自H、OR O 、CH 2 OH、CO 2 H、NHSO 2 Me和NHCOMe; R A2 和R A6 独立选择自H、卤素和OR O ; 或R A3 和R A4 与它们连接的碳原子一起,或RA2和R A3 与它们连接的碳原子一起,可形成含有至少一个氮环原子的C 5-6 杂环或杂芳环; 如果X不是N,则R A2 至R A6 中的1、2或3个不是H; C为: 其中X选自N和CH,Y选自N和CH,Z选自N和CR C6 ; R C3 选自H、卤素和可选择性取代的含氮C 5-7 杂环基; R C5 为以下组合之一: 该组合可由一个或两个C 1-4 烷基或一个羧基选择; R C6 为H; 或者,当X和Y为N时,R C5 和R C6 (当Z为CR C6 时)与它们连接的碳原子可形成所选自的融合C 6 芳香环之一:
  • Therapeutic heterocyclic compounds
    申请人:——
    公开号:US20030013708A1
    公开(公告)日:2003-01-16
    Provided herein is a compound having the formula (I): 1 Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT 1B and 5HT 1D antagonists.
    本文提供的化合物具有以下式(I): 其中所述化合物可用于治疗精神障碍,包括但不限于抑郁症、广泛性焦虑、进食障碍、痴呆症、恐慌障碍和睡眠障碍。这些化合物还可能用于治疗胃肠道障碍、心血管调节、运动障碍、内分泌障碍、血管痉挛和性功能障碍。这些化合物是5HT 1B和5HT 1D拮抗剂。
  • Therapeutic chromone compounds
    申请人:——
    公开号:US20040087575A1
    公开(公告)日:2004-05-06
    Provided herein is a compound of the formula (I) wherein said compound is useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating, disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT 1B antagonists. Also provided herein are processes for making compounds of Formula (I) and intermediate compounds.
    本文提供的是一种化合物,其化学式为(I),其中该化合物可用于治疗包括但不限于抑郁症、广泛性焦虑、进食障碍、痴呆症、恐慌障碍和睡眠障碍在内的精神疾病。这些化合物也可能对治疗胃肠道疾病、心血管调节、运动障碍、内分泌失调、血管痉挛和性功能障碍有用。这些化合物是5HT 1B 拮抗剂。本文还提供了制备化合物(I)和中间体化合物的方法。
  • Therapeutic chroman compounds
    申请人:——
    公开号:US20040110745A1
    公开(公告)日:2004-06-10
    Provided herein is a compound represented by the Formula (I) wherein said compounds are useful for the treatment of migraine. Also provided are processes for the preparation of compounds of Formula (I) and intermediates.
    本文提供的是一种化合物,其化学式表示为(I),其中这些化合物对治疗偏头痛有用。还提供了制备化合物(I)和中间体的方法。
查看更多